免疫调节基因的多态性与Graves病易感性的相关性研究进展

doi:10.16352/j.issn.1001-6325.2023.03.495

基础医学与临床 ›› 2023, Vol. 43 ›› Issue (3): 495-499.doi: 10.16352/j.issn.1001-6325.2023.03.495

免疫调节基因的多态性与Graves病易感性的相关性研究进展

王玉洁^1,2, 杨孟迪^1,2, 何风英^1,2, 丁雨露^1,2, 孙琳楠^1,2, 甄东户^2*

1.兰州大学第一临床医学院内分泌科,甘肃兰州 730030;
2.兰州大学第一医院内分泌科,甘肃兰州 730030

收稿日期:2021-11-04 修回日期:2022-05-07 出版日期:2023-03-05 发布日期:2023-02-27
通讯作者: * zhdh8279@163.com
基金资助:
上海市医药卫生发展基金会糖尿病临床研究项目(Ⅰ期10研究);标准化代谢性疾病管理中心(MMC)专项研究基金(2018-mmczxjj-3);甘肃省自然科学基金(21JR1RA096);甘肃省内分泌疾病临床医学研究中心(20JR10FA667)

Research progress on the correlation between polymorphism of immunoregulatory gene and susceptibility to Graves' disease

WANG Yujie^1,2, YANG Mengdi^1,2, HE Fengying^1,2, DING Yulu^1,2, SUN Linnan^1,2, ZHEN Donghu^2*

1. Department of Endocrinology,the First College of Clinical Medicine,Lanzhou University,Lanzhou 730030;
2. Department of Endocrinology,the First Hospital of Lanzhou University,Lanzhou 730030,China

Received:2021-11-04 Revised:2022-05-07 Online:2023-03-05 Published:2023-02-27
Contact: * zhdh8279@163.com

摘要/Abstract

摘要： Graves病(GD)是一种遗传背景强的器官特异性自身免疫性疾病,其核心发病环节是免疫因素,但遗传因素在其发病机制中也起到重要作用。GD的易感基因主要分为免疫调节基因和甲状腺特异性基因,其中免疫调节基因多态性可通过各种机制影响GD的易感性,故可为进一步研究GD的易感基因及发病机制提供新的思路。

关键词: Graves病, 易感基因, 基因多态性, 免疫调节基因

Abstract: Graves' disease(GD)is an organ-specific autoimmune disease with genetic background. The core pathogenesis of GD is immune factors, but genetic factors also play an important role in it. The susceptibility genes of GD are mainly divided into immunoregulatory gene and thyroid specific gene. The polymorphism of immunoregulatory gene may have some impact on the susceptibility of GD through various mechanisms, which may provide new ideas for the further study of the susceptibility genes and pathogenesis of GD.

Key words: Graves' disease, susceptibility gene, gene polymorphism, immunoregulatory gene

中图分类号:

R581.1

王玉洁, 杨孟迪, 何风英, 丁雨露, 孙琳楠, 甄东户. 免疫调节基因的多态性与Graves病易感性的相关性研究进展[J]. 基础医学与临床, 2023, 43(3): 495-499.

WANG Yujie, YANG Mengdi, HE Fengying, DING Yulu, SUN Linnan, ZHEN Donghu. Research progress on the correlation between polymorphism of immunoregulatory gene and susceptibility to Graves' disease[J]. Basic & Clinical Medicine, 2023, 43(3): 495-499.

参考文献

[1]Dvornikova KA, Bystrova EY, Platonova ON, et al. Polymorphism of Toll-like receptor genesand autoimmune endocrine diseases[J]. Autoimmun Rev, 2020, 19:102496.doi:10.1016/j.autrev.2020.102496.
[2]Shehjar F, Dil A, Misgar RA, et al. A significant association of the CTLA4 gene variants with the risk of autoimmune Graves' disease in ethnic Kashmiri population[J]. Cell Immunol, 2020, 347:103995.doi:10.1016/j.cellimm.2019.103995.
[3]Hosseini A, Gharibi T, Marofi F, et al. CTLA-4: from mechanism to autoimmune therapy[J]. Inter Immunophacol, 2020, 80:106221.doi:10.1016/j.intimp.2020.106221.
[4]Sun W, Zhang X, Wu J, et al. Correlation of TSHR and CTLA-4 single nucleotide polymorphisms with Graves' disease[J]. Inter J Genomics, 2019, 2019:6982623.doi:10.1155/2019/6982623.
[5]葛绾宇, 孙卫华, 张晓梅, 等. 4p14区段和CTLA-4基因多态性与Graves病相关[J]. 基础医学与临床, 2016, 36:1246-1251.
[6]Huang F, He Q, Jiao X, et al. Meta-analysis of CTLA-4 +49 gene polymorphism and susceptibility to Graves' disease[J]. Crit Rev Eukaryot Gene Expr, 2020, 30:377-390.
[7]Chen X, Hu Z, Liu M, et al. Correlation between CTLA-4 and CD40 gene polymorphisms and their interaction in graves' disease in a Chinese Han population[J]. BMC Med Genet, 2018, 19:171.doi:10.1186/s12881-018-0665-y.
[8]Bufalo NE, Dos Santos RB, Rocha AG, et al. Polymorphisms of the genes CTLA4, PTPN22, CD40, and PPARG and their roles in Graves' disease: susceptibility and clinical features[J]. Endocrine, 2021, 71:104-112.
[9]Wawrusiewicz-Kurylonek N, Koper-Lenkiewicz OM, Gos＇cik J, et al. Association of PTPN22 polymorphism and its correlation with Graves' disease susceptibility in Polish adult population-A preliminary study[J]. Mol Genet Genomic Med, 2019, 7:e661.doi:10.1002/mgg3.661.
[10]Wu H, Wan S, Qu M, et al. The relationship between PTPN22 R620W polymorphisms and the susceptibility to autoimmune thyroid diseases: an updated meta-analysis[J]. Immunol Invest, 2022, 51:438-451.
[11]Wang XM, Tu JC. TNFSF15 is likely a susceptibility gene for systemic lupus erythematosus[J]. Gene, 2018, 670:106-113.
[12]Yang GL, Han Z, Xiong J, et al. Inhibition of intra-cranial hemangioma growth and hemorrhage by TNFSF15[J]. FASEB J, 2019, 33:10505-10514.
[13]Okamoto M, Watanabe M, Inoue N, et al. Gene polymorphisms of VEGF and VEGFR2 are associated with the severity of Hashimoto's disease and the intractability of Graves' disease, respectively[J]. Endocr J, 2020, 67:545-559.
[14]Abe I, Islam F, Lo CY, et al. VEGF-A/VEGF-B/VEGF-C expressions in non-hereditary, non-metastatic phaeochromocytoma[J]. Histol Histopathol, 2021, 36:645-652.
[15]Zhao H, Zhang Q. Signaling in TNFSF15-mediated suppression of VEGF production in endothelial cells[J]. Methods Mol Biol(Clifton, N.J.), 2021, 2248:1-18.
[16]钟霞, 赵家军, 戴晓华, 等. VEGF、IGF-Ⅰ与Graves病患者甲状腺内血管形成的关系[J]. 中华内分泌代谢杂志, 2006, 119-120.
[17]Zhang M, Liu S, Xu J, et al. TNFSF15 polymorphisms are associated with Graves' disease and Graves' ophthalmopathy in a Han Chinese population[J]. Curr Eye Res, 2020, 45:888-895.
[18]Fallahi P, Ferrari SM, Elia G, et al. Cytokines as targets of novel therapies for Graves' ophthalmopathy[J]. Front Endocrinol, 2021, 12:654473.doi:10.3389/fendo.2021.654473.
[19]Maklakova TP, Zorina VN, Yanysheva AV, et al. Immunoregulatory proteins and cytokines in the blood of patients with Graves' disease[J]. Probl Endokrinol, 2019, 65:4-9.
[20]Zhu Q, Su J, Wang X, et al. Serum concentrations of TNF-α and its soluble receptors in Graves' disease[J]. Endocr Connect, 2020, 9:736-746.
[21]Ferrari SM, Fallahi P, Elia G, et al. Novel therapies for thyroid autoimmune diseases: an update[J]. Best Pract Res Clin Endocrinol Metab, 2020, 34:101366.doi:10.1016/j.beem.2019.101366.
[22]Boskovic O, Medenica S, Radojevic N, et al. Etanercept in the treatment of Graves' ophthalmopathy with primary hypothyroidism and rheumatoid arthritis[J]. Cent Eur J Immunol, 2019, 44:463-465.
[23]Hirai N, Watanabe M, Inoue N, et al. Association of IL6 gene methylation in peripheral blood cells with the development and prognosis of autoimmune thyroid diseases[J]. Autoimmunity, 2019, 52:251-255.
[24]Zhu P, Wu X, Zhou J, et al. Gene polymorphisms of pro-inflammatory cytokines may affect the risk of Graves' disease: a Meta-analysis[J]. J Endocrinol Invest, 2021, 44:311-319.

免疫调节基因的多态性与Graves病易感性的相关性研究进展

Research progress on the correlation between polymorphism of immunoregulatory gene and susceptibility to Graves' disease

PDF

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

本文评价

[1]	邹文兵, 王安仙, 曹政媛. 贵阳地区原发性高血压患者降压药物疗效相关基因的多态性[J]. 基础医学与临床, 2024, 44(7): 979-983.
[2]	田晓怡, 刘颖, 姚瑶, 顾秀丽, 李爱华, 郑胡镛, 宋文琪. 儿童急性淋巴细胞白血病ABCB1、ABCC4和SLCO1B1多态性与大剂量MTX血药浓度及不良反应的相关性[J]. 基础医学与临床, 2022, 42(5): 708-713.
[3]	覃意往, 莫梅香, 张龙炯, 罗银亚, 韦良银, 胡季芳, 鲁衍强. 贵州省荔波县汉族和布依族女性MTHFR与MTRR多态性的分布[J]. 基础医学与临床, 2021, 41(5): 694-697.
[4]	叶阿里, 邹雨桐, 张海燕, 吴洁, 张睿, 张晓峰, 马庆伟. MALDI-TOF-MS和RT-qPCR对于SLCO1B1和ApoE多态性检测的比较[J]. 基础医学与临床, 2020, 40(7): 980-985.
[5]	郭婷婷, 刘芳, 归婧, 杨小风. 郑州市中原区汉族育龄女性MTHFR和MTRR基因多态性[J]. 基础医学与临床, 2020, 40(2): 215-218.
[6]	许可阳洪波潘慧. 重组人生长激素治疗成人生长激素缺乏症患者疗效的相关基因多态性[J]. 基础医学与临床, 2018, 38(5): 731-734.
[7]	王晓菲刘军连司少艳. Toll样受体与特应性皮炎的研究进展 [J]. 基础医学与临床, 2014, 34(6): 853-856.
[8]	杜明艳丁文军封靖杜会山. 血管紧张素转化酶基因I/D多态性与脑梗死后抑郁相关[J]. 基础医学与临床, 2012, 32(9): 1040-1043.
[9]	侯广道莫新玲. 2型糖尿病与动脉粥样硬化相关性研究进展[J]. 基础医学与临床, 2012, 32(12): 1488-1491.
[10]	杜明艳丁文军杜会山封靖. ACE、AGT基因联合多态性与高血压合并脑梗塞的相关性 [J]. 基础医学与临床, 2011, 31(11): 1189-1193.
[11]	国雪. PAI-1启动子区4G/5G基因多态性、ACE插入/缺失多态性与脑卒中的相关研究 [J]. 基础医学与临床, 2011, 31(11): 1238-1241.
[12]	钟发德;张莉娜;徐进;张月苗;费丽娟;陈东妮. α-adducin G460T和AGT M235T基因多态性与原发性高血压发病风险相关[J]. 基础医学与临床, 2011, 31(1): 62-67.
[13]	韩秀玲沈志霞李宏芬张志纺王贺永张淑青吴寿岭. 血管紧张素转换酶基因I/D多态性与血脂水平及原发性高血压的相关性探讨[J]. 基础医学与临床, 2010, 30(8): 843-846.
[14]	冯磊光邵春青刘英慧陶永红郝潇蕾. 重型抑郁症患者亚甲基四氢叶酸还原酶基因多态性检测[J]. 基础医学与临床, 2010, 30(8): 811-814.
[15]	陶晓明李国江侯淑琴萧占森佟伟军刘永跃吴刚张永红邱长春. 胆固醇脂转移蛋白基因 TaqⅠB多态性与蒙古族原发性高血压的相关性[J]. 基础医学与临床, 2010, 30(7): 677-682.